Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI tailors blood pressure advice: could personalized texts beat pamphlets?

NCT ID NCT07776834

Disease control Sponsor: Akdeniz University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study tests whether personalized education generated by artificial intelligence can help adults with hypertension learn more about their condition and take their medication more consistently, compared to a standard printed booklet. About 88 adults with high blood pressure will receive either the usual printed information or AI-crafted lessons delivered over four weeks via WhatsApp or SMS, voice messages, and brief phone calls. Researchers will measure changes in hypertension knowledge, medication adherence confidence, and blood pressure from the start to the fifth week.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Generative AI-supported personalized hypertension education delivered via WhatsApp/SMS, voice messages, and phone follow-up
What this could lead to
If effective, this approach could offer a scalable, low-cost way to help people with hypertension better manage their condition and stick to their medication.
What could go wrong
The trial is small (88 participants) and short-term, so results may not apply broadly. The effect may be modest, and the intervention relies on participants' ability to use messaging apps.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

88 people

The number who actually took part.

Started

Jun 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Voluntary agreement to participate in the study * Diagnosis of hypertension * Use of antihypertensive medication for at least 6 months * Medication adherence self-efficacy score of 26 or lower * Age 18 years or older * Ability to read and write in Turkish * General health status adequate for communication * Ability to read SMS messages and use WhatsApp Exclusion Criteria: * Withdrawal from the study after enrollment * Inability to be reached by telephone during the follow-up period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertansion are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder Medication Adherence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertansion

Contacts and locations

Locations

  • Akdeniz University Hospital

    Antalya, Antalya, 07070, Turkey (Türkiye)